Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 09, 2015 5:32 PM ET


Company Overview of Curemark, LLC

Company Overview

Curemark, LLC, a biotechnology company, develops and markets compounds for children and adults with neurological disorders. The company focuses on addressing the health needs of individuals in the areas of neurology with dysautonomic components; and gastrointestinal/pancreatic secretory deficiencies. It develops CM-AT, a treatment for autism; CM-4612 for attention deficit hyperactivity disorder; CM-PK, a compound for Parkinson’s disease; CM-182 for schizophrenia; and CM-1212, a drug for the treatment of alcohol and drug addicted individuals. The company was founded in 2004 and is based in Rye, New York.

411 Theodore Fremd Avenue

Suite 206 South

Rye, NY 10580

United States

Founded in 2004





Key Executives for Curemark, LLC

Founder, Chief Executive Officer and Director
Vice President of Finance
Senior Vice President of Operations
Senior Scientist and Member of Scientific Advisory Board
Vice President of Research and Product Development
Compensation as of Fiscal Year 2015.

Curemark, LLC Key Developments

Curemark, LLC Presents at Rodman & Renshaw 17th Annual Global Investment Conference, Sep-10-2015 10:50 AM

Curemark, LLC Presents at Rodman & Renshaw 17th Annual Global Investment Conference, Sep-10-2015 10:50 AM. Venue: The St. Regis Hotel, Two East 55th Street, New York, NY 10022, United States.

Curemark, LLC Launches New Phase III Trial in Expanded Population of Children with Autism

Curemark, LLC announced the start of a new Phase III double blind, randomized, placebo-controlled clinical trial to examine the effect of its novel formulation, CM-AT, on all children ages 3-8 with Autism. Previously, the company announced the successful results of its FDA Phase III double blinded clinical trial for CM-AT in children ages 3-8 with Autism who had low levels of the digestive enzyme chymotrypsin. This new trial will help determine whether all children with Autism could potentially benefit from CM-AT.

Curemark, LLC Receives Patent for Enzyme Delivery System

Curemark, LLC, announced that the company has been awarded 6 new patents for its enzyme delivery system. The new patents, issued in Europe, Australia and Central America, extend to 2030 and can be utilized for multiple enzyme products including CM-AT, Curemark's proprietary autism drug.

Similar Private Companies By Industry

Company Name Region
KinDex Pharmaceuticals, Inc. United States
CoDa Therapeutics, Inc. United States
NeuroTrack Technologies, Inc. United States
Verex Laboratories, Inc. United States
NeXtGen Biologics, Inc. United States

Recent Private Companies Transactions

Private Placement
June 26, 2015
Private Placement
December 30, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Curemark, LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at